» Authors » Thomas Rogier

Thomas Rogier

Explore the profile of Thomas Rogier including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 23
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Jarrot P, Mirouse A, Ottaviani S, Cadiou S, Salmon J, Liozon E, et al.
Hum Vaccin Immunother . 2024 Apr; 20(1):2334084. PMID: 38563792
We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant...
2.
Samson M, Nicolas B, Ciudad M, Greigert H, Guilhem A, Cladiere C, et al.
Eur J Intern Med . 2022 Jun; 102:104-109. PMID: 35690570
Introduction: This study aimed to identify markers of disease worsening in patients hospitalized for SARS-Cov2 infection. Patients And Methods: Patients hospitalized for severe recent-onset (<1 week) SARS-Cov2 infection were prospectively...
3.
De Guglielmo W, Rebibou J, Aho S, Rogier T, Nuemi G, Girard C, et al.
Healthcare (Basel) . 2022 Mar; 10(3). PMID: 35327036
This study sought to identify risk factors for acute kidney injury (AKI) from pre-operative variables in a population of subjects aged over 65. Eligible patients were aged 65 years or...
4.
Rogier T, Eberl I, Moretto F, Sixt T, Catherine F, Esteve C, et al.
Eur J Clin Microbiol Infect Dis . 2021 Mar; 40(9):2023-2028. PMID: 33686557
During an epidemic period, we compared patients hospitalized for initial suspicion of COVID-19 but for whom an alternative diagnosis was finally retained (n = 152) with those who had COVID-19...
5.
Sixt T, Moretto F, Devilliers H, Abdallahoui M, Eberl I, Rogier T, et al.
J Infect . 2020 Sep; 82(2):282-327. PMID: 32998039
No abstract available.
6.
Rogier T, Samson M, Mourey G, Falvo N, Magy-Bertrand N, Ouandji S, et al.
J Clin Med . 2020 Jul; 9(6). PMID: 32630482
Immune thrombocytopenia (ITP) is a rare autoimmune disease due to autoantibodies targeting platelet glycoproteins (GP). The mechanism of platelet destruction could differ depending on the specificity of antiplatelet antibodies: anti-GPIIb/IIIa...